Phosphatidylserine

PS stood out because its cognitive evidence extends across multiple human studies rather than depending on a single favorable result. A 2022 systematic review identified nine human studies using 100 to 300 mg per day, including five randomized controlled trials that could be pooled for memory outcomes. The pooled effect was SMD = 0.22.

That represents a modest but real cognitive effect, roughly equivalent to moving an average result from the 50th percentile to about the 59th percentile at the group level. PS has also shown very good tolerability across the studied dose range.

We also found the combination of PS with DHA compelling mechanistically.

Both are important constituents of neuronal membranes. Brain PS is naturally rich in DHA, and DHA-containing phospholipids are particularly favorable substrates for PS synthesis. DHA can increase the amount of PS in neuronal membranes, including DHA-rich PS species, while PS provides the membrane environment needed for a range of signaling proteins to function normally. Taken together, there is a plausible mechanism by which PS and DHA can reinforce healthy membrane composition, fluidity, and signaling rather than simply acting as two unrelated ingredients.

There is also solid human research directly combining PS with omega-3 fatty acids (see below) to improve certain cognitive measures.

One particularly salient randomized trial enrolled 157 non-demented older adults with memory complaints and compared placebo with a PS-DHA preparation for 15 weeks.

The active group received 300 mg of phosphatidylserine per day, exactly the amount of PS in Goldmind:Focus, together with DHA and EPA. Immediate verbal recall improved significantly compared with placebo.

Using the published group means, standard errors, and analyzable sample sizes, the difference in immediate-recall improvement corresponds to an approximate standardized effect of d≈0.29. That calculation is ours rather than an effect size reported by the investigators, but it gives a useful sense of magnitude: approximately the difference between the 50th and 61st percentile at the group level.

Goldmind:Focus provides PS at the frequently studied 300 mg daily dose, a likely optimal dose balancing cognitive effects with tolerability across many populations.

The broader systematic review included doses from 100 to 300 mg daily over six weeks to six months. The 300 mg level appears repeatedly in the human literature and was also well tolerated in the 15-week PS-DHA randomized trial.

Phosphatidylserine is different from Rhodiola in its time course. It is not a component of Goldmind:Focus we expect most people to immediately notice a benefit from after a single dose.

The human studies generally evaluate PS over several weeks to several months. Rhodiola provides the earliest signal, while PS is part of the benefit we find with consistent use over a medium-term of several weeks.

There does not need to be an obvious sensation after taking PS for it to be doing anything useful. We contextualize PS as providing some of the building blocks for healthy neuronal structure and function over a longer timeline.

Phosphatidylserine has generally been very well tolerated in human studies.

In the 157-person PS-DHA trial, 300 mg of PS daily for 15 weeks produced no significant differences from placebo in the measured biochemical or hematologic safety parameters, blood pressure, or heart rate.

Goldmind:Focus uses soy-derived phosphatidylserine and contains soy. Anyone with a soy allergy should not use the product. People who are pregnant or nursing, take medications, or have a medical condition should discuss use with a healthcare professional.

PS is a consistently positive contributor, but perhaps not a superstar. The overall cognitive effect is modest, but there is a genuine signal, especially for memory, across randomized trials. The frequently studied 300 mg dose has been well tolerated, and its role as a major neuronal membrane phospholipid makes particular sense alongside DHA.